# Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

> **NCT04479267** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Barbara Ann Karmanos Cancer Institute** · enrollment: 8 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma
- High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements
- High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements
- Double Expressor Lymphoma
- High-grade B-cell Lymphoma

## Interventions

- **DRUG:** Prednisone
- **DRUG:** Prednisolone
- **DRUG:** Methylprednisolone
- **BIOLOGICAL:** Rituximab
- **DRUG:** Polatuzumab Vedotin
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin Hydrochloride

## Key facts

- **NCT ID:** NCT04479267
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-21
- **Primary completion:** 2025-06-19
- **Final completion:** 2026-07-19
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04479267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04479267, "Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04479267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*